Iquix, Levaquin, Quixin, Quinsair (levofloxacin) is a small molecule pharmaceutical. Levofloxacin was first approved as Iquix on 1996-12-20. It is used to treat bacterial eye infections, bacterial infections, bacterial pneumonia, bacterial skin diseases, and bronchitis amongst others in the USA. It has been approved in Europe to treat cystic fibrosis and respiratory tract infections. Levofloxacin's patent is valid until 2022-02-26 (FDA).
|Indication||bacterial eye infections, bacterial infections, bacterial pneumonia, bacterial skin diseases, bronchitis, chlamydia infections, cystic fibrosis, escherichia coli infections, haemophilus infections, klebsiella infections, legionnaires' disease, maxillary sinusitis, mycoplasma infections, proteus infections, protozoan infections, pseudomonas infections, pulmonary tuberculosis, pyelonephritis, respiratory tract infections, salmonella infections, soft tissue infections, staphylococcal infections, streptococcal infections, urinary tract infections|
|Drug Class||Antibacterials (quinolone derivatives)|